Iranian Journal of Radiology

Published by: Kowsar

Endovascular Treatment with Drug-Coated Balloons in Femoropopliteal Artery Disease

Ibrahim Ilker Oz 1 , * , Muammer Bilici 2 , Namik Kemal Altinbas 3 , Evrim Bozay Oz 4 and Emrah Caglar 1
Authors Information
1 Department of Radiology, Bulent Ecevit University, School of Medicine, Zonguldak, Turkey
2 Department ofInternal Medicine, Bulent Ecevit University School of Medicine, Zonguldak, Turkey
3 Department of Radiology , Ankara University, School of Medicine, Ankara, Turkey
4 Department of Anesthesiology and Reanimation, Zonguldak State Hospital, Zonguldak, Turkey
Article information
  • Iranian Journal of Radiology: January 2018, 15 (1); e61841
  • Published Online: November 17, 2017
  • Article Type: Research Article
  • Received: July 4, 2016
  • Revised: February 15, 2017
  • Accepted: April 29, 2017
  • DOI: 10.5812/iranjradiol.61841

To Cite: Ilker Oz I, Bilici M, Kemal Altinbas N, Bozay Oz E, Caglar E. Endovascular Treatment with Drug-Coated Balloons in Femoropopliteal Artery Disease, Iran J Radiol. 2018 ; 15(1):e61841. doi: 10.5812/iranjradiol.61841.

Copyright © 2017, Iranian Journal of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Catheter Cardiovasc Interv. 2015;86(4):611-25. doi: 10.1002/ccd.26122. [PubMed: 26256456].
  • 2. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373(2):145-53. doi: 10.1056/NEJMoa1406235. [PubMed: 26106946].
  • 3. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW, Martin EC, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a Special Writing Group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. J Vasc Interv Radiol. 2003;14(9 Pt 2):S495-515. [PubMed: 14514865].
  • 4. Tsetis D, Uberoi R. Quality improvement guidelines for endovascular treatment of iliac artery occlusive disease. Cardiovasc Intervent Radiol. 2008;31(2):238-45. doi: 10.1007/s00270-007-9095-5. [PubMed: 18034277].
  • 5. Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res. 2015;116(9):1599-613. doi: 10.1161/CIRCRESAHA.116.303503. [PubMed: 25908731].
  • 6. Franzone A, Stabile E, Trimarco B, Esposito G. Peripheral drug-eluting technology. Cardiol Clin. 2015;33(1):151-62. doi: 10.1016/j.ccl.2014.09.005. [PubMed: 25439337].
  • 7. Banerjee S, Sarode K, Mohammad A, Brilakis ES. Drug-coated balloon and stent therapies for endovascular treatment of atherosclerotic superficial femoral artery disease. Curr Cardiol Rep. 2015;17(5):36. doi: 10.1007/s11886-015-0586-8. [PubMed: 25894799].
  • 8. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655-64. doi: 10.1016/S0140-6736(15)60657-2. [PubMed: 26334160].
  • 9. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wohrle J, Jeger R, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013;102(11):785-97. doi: 10.1007/s00392-013-0609-7. [PubMed: 23982467].
  • 10. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. [PubMed: 18779447].
  • 11. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689-99. doi: 10.1056/NEJMoa0706356. [PubMed: 18272892].
  • 12. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831-40. doi: 10.1161/CIRCINTERVENTIONS.112.971630. [PubMed: 23192918].
  • 13. Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19(5):571-80. doi: 10.1583/JEVT-12-3926MR.1. [PubMed: 23046320].
  • 14. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022. [PubMed: 24456716].
  • 15. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495-502. doi: 10.1161/CIRCULATIONAHA.114.011004. [PubMed: 25472980].
  • 16. van Overhagen H, Spiliopoulos S, Tsetis D. Below-the-knee interventions. Cardiovasc Intervent Radiol. 2013;36(2):302-11. doi: 10.1007/s00270-013-0550-1. [PubMed: 23354963].
  • 17. Perez de Prado A, Perez-Martinez C, Cuellas Ramon C, Regueiro Purrinos M, Diego Nieto A, Gonzalo-Orden JM, et al. Safety and efficacy of different paclitaxel-eluting balloons in a porcine model. Rev Esp Cardiol (Engl Ed). 2014;67(6):456-62. doi: 10.1016/j.rec.2013.09.030. [PubMed: 24863594].
  • 18. Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, et al. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2009;37(3):336-42. doi: 10.1016/j.ejvs.2008.12.001. [PubMed: 19112033].
  • 19. Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability. J Endovasc Ther. 2016;23(2):356-70. doi: 10.1177/1526602815626557. [PubMed: 26823485].
  • 20. Heilmann T, Richter C, Noack H, Post S, Mahnkopf D, Mittag A, et al. Drug release profiles of different drug-coated balloon platforms. Eur Cardiol. 2010;6(4):40-4.
  • 21. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921-9. doi: 10.1016/j.jacc.2005.09.065. [PubMed: 16516072].
  • 22. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb. 1998;5(1):29-35. [PubMed: 10077455].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments